Nexavar Effective in Advanced HCC: Phase III Trial Stopped

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Nexavar Effective in Advanced HCC: Phase III Trial Stopped

WEST HAVEN, Connecticut—Bayer and Onyx (Emeryville, California) have stopped the phase III SHARP trial of sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma (HCC), based on the recommendation of an independent monitoring committee after interim data showed that the trial had met its primary endpoint. Patients in the Nexavar arm achieved a "superior overall survival," compared to those in the placebo arm, and adverse events were similar in both arms, the companies said in a press release. All patients enrolled in the trial are now being given access to Nexavar.

Recent Videos
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content